Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

Huali Wu,1 Jeffrey R Infante,2 Vicki L Keedy,3 Suzanne F Jones,2 Emily Chan,3 Johanna C Bendell,2 Wooin Lee,4 Whitney P Kirschbrown,1 Beth A Zamboni,5 Satoshi Ikeda,6 Hiroshi Kodaira,6 Mace L Rothenberg,3 Howard A Burris III,2 William C Zamboni1,7–9 1UNC Eshelman School of Pharmacy, Unive...

Full description

Bibliographic Details
Main Authors: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC
Format: Article
Language:English
Published: Dove Medical Press 2015-02-01
Series:International Journal of Nanomedicine
Online Access:http://www.dovepress.com/factors-affecting-the-pharmacokinetics-and-pharmacodynamics-of-pegylat-peer-reviewed-article-IJN

Internet

http://www.dovepress.com/factors-affecting-the-pharmacokinetics-and-pharmacodynamics-of-pegylat-peer-reviewed-article-IJN

Similar Items